Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Cadila Healthcare — Investor Presentation (May 2016)
19 slides from Zydus Lifesciences's investor presentation, May 2016
Slide 1: Cadila Healthcare Limited Investor Presentation
Cadila Healthcare Limited Investor Presentation May 2016
Slide 2: Well integrated pharma player with global footprints
Well integrated pharma player with global footprints > 60 years 9th largest 1st Indian Company Generic co. in US in To discover & develop an Operational experience terms of prescriptions NCE in-house : Lipaglyn (Saroglitazar) ~ $ 1.5bn Among top 5 1st Company Pharmaceutical To launch biosimilar of G
Slide 3: Track Record of Value Creation
Track Record of Value Creation… INR Bn. … which gave us Total Income from significant external Operations recognition INR Bn. CII Industrial Net Profit Innovation Awards 2015 INR Bn. Market CNBC – TV 18 Capitalisation India * Innovator Award 2013 3 * Market Capitalisation is calculated by applying t
Slide 4: Key businesses for ZyNext journey
Key businesses for ZyNext journey Zydus Formulations Business Other Businesses and Emerging – Key Markets Alliances Businesses ▪ US ▪ EU Formulations ▪ Biosimilars ▪ India ▪ Consumer ▪ Vaccines ▪ Latin America Wellness ▪ NCEs ▪ Emerging Markets ▪ Animal Health – Asia, Africa ▪ APIs ▪ JVs & alliances
Slide 5: Key Financial Numbers – FY 2015-16
Key Financial Numbers – FY 2015-16 Consolidated (Rs. Mio.) Amount Gr.% Segment-wise Gross Sales * Total Income from Operations 98,376 13.7% India Form., EBIDT 23,829 35.7% 31% JVs ,5% EBIDT % to Income from Ops. 24.2% APIs, 4% Profit before tax 21,236 46.9% Animal Health, 3% PBT % to Income from Ops
Slide 6: US formulations – 9th largest generic player
US formulations – 9th largest generic player (based on scripts) Market size* : ~$ 68 bn Aspirations Market growth* : 4%+ Zydus size** : ~ $ 614 mn Be amongst the top 10 generic cos. in US with continued strong focus on customer needs Zydus growth** : 10% One of the significant contributors to re
Slide 7: US formulations – strong product pipeline
US formulations – strong product pipeline Growing Focus on Complex Generics Modified Release Oral Solids Immediate Release Oral Solids Transdermals Injectables Topicals Controlled Substances Nasal Sprays Total Approved ANDAs – 103(1) Total ANDAs Pending Approval – 166 As on March 31, 2016 As on Marc
Slide 8: India formulations – 4th largest player
India formulations – 4th largest player Aspirations Market size* : Rs. 980 bn+ Market growth* : 13% Leadership in CVS, female healthcare and pain mgt. area, Zydus size** : Rs. 41 bn+ among top 5 players in GI, respiratory and derma Market Share** : 4.25% Continue to be one of the significant con
Slide 9: Latin America formulations
Latin America formulations Aspirations : To establish strong base with aggressive product launches Brazil Presence in branded generics and generic generics segments with a continued focus on brand building initiatives Robust product pipeline from India - 95 filings, 40 approvals Mkt. Size* : ~ B
Slide 10: Emerging Markets formulations
Emerging Markets formulations Market size* : ~ $ 13 bn Aspirations Market growth* : ~ 12-13% To strengthen the position in different markets of Zydus size** : Rs. 4,760 mn Asia and Africa Zydus growth** : 17% Strengths to be leveraged Operations in different markets of Asia Pacific and Africa an
Slide 11: Other businesses (1/2)
Other businesses (1/2) Aspirations : To be a relevant player in generic markets of France and EU formulations Spain Mkt. Size* : ~Euro Among top 10 in France, among top 20 in Spain Mkt. Size* : ~Euro+5.4 5.4 bn (France bn (France + Spain Gx) Expansion through new products : launched 145+ molecul
Slide 12: Other Businesses (2/2)
Other Businesses (2/2) Animal Health Aspirations : To be a comprehensive, global animal healthcare provider One of India’s leading animal healthcare players. Acquired select brands and manufacturing operations in India from Zoetis, a Zydus Size *: global animal healthcare company so as to expand
Slide 13: Joint Ventures and Alliances – leveraging strengths
Joint Ventures and Alliances – leveraging strengths Aspirations : Value creation through win-win alliances and be a partner of choice Zydus Takeda JV Zydus Hospira JV State-of-the-art mfg. facility for APIs of Takeda State-of-the-art cytotoxic facility approved by leading authorities like MHRA,
Slide 14: Strong focus on R&D
Strong focus on R&D • Capability : target identification, pre-clinical research and early clinical development • 250+ dedicated scientists NCEs • 5 NCEs in pipeline • Launched Lipaglyn, the first NCE of India • 600+ dedicated scientists for • 70+ dedicated scientists development of generics for • St
Slide 15: Biosimilars and Vaccines – emerging businesses
Biosimilars and Vaccines – emerging businesses Aspirations : Leverage technological edge to unlock substantial value and create pillars for future growth. Strengths to be leveraged Biosimilar pipeline Pre- Regulatory Mktg. Biosimilars No Product Indication Cloning Process Devp. Clinical Permissio Cl
Slide 16: NCE Research
NCE Research Aspirations : Add more NCEs in pipeline to drive towards becoming a research based pharma co. by 2020 Key strengths NCE Pipeline Pre- State-of-the art research facility Drug Lead clinical Project Target Indication optimi- IND Phase I Phase II Phase III NDA Discovery Develop- Capabil
Slide 17: World class infrastructure to support ZyNext journey
World class infrastructure to support ZyNext journey Ahmedabad Formulations Oral Solids (Moraiya) Oral Solids (SEZ) India U.S. Topicals Transdermal (SEZ) Alidac Pharma (SEZ) Lyophilised Inj. (Vatva) Sikkim Biologics Oral Solids and Gel Bulk – I Consumer Wellness Bulk – II Fill and Finish Baddi Vacci
Slide 18: Key strategies for ZyNext journey
Key strategies for ZyNext journey Strong execution focus for the U.S. market; drive growth with continuous focus on product 1 launches 2 Focus on difficult to develop and manufacture and specialty products to improve margins In India, focus on high growth Therapeutic Areas, outperform the domestic m
Slide 19: Thank You. Safe Harbour Statement
Thank You. Safe Harbour Statement This presentation may include certain “forward looking statements” , based on current expectations, within the meaning of applicable laws and regulations. Actual results may differ and the company does not guarantee realization of these statements. The Company also